Q4 Earnings Estimate for Biogen Issued By Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Leerink Partnrs decreased their Q4 2025 earnings per share estimates for shares of Biogen in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of $3.20 for the quarter, down from their previous estimate of $3.40. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, beating the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.32 billion. During the same period last year, the business earned $5.28 EPS. The business’s revenue was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

Several other brokerages have also recently weighed in on BIIB. Morgan Stanley dropped their price objective on Biogen from $146.00 to $144.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Wall Street Zen upgraded Biogen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 28th. William Blair reiterated an “outperform” rating on shares of Biogen in a research note on Wednesday, September 24th. Piper Sandler lifted their target price on Biogen from $115.00 to $118.00 and gave the stock a “neutral” rating in a research note on Friday, September 12th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Biogen in a research note on Wednesday. Eleven equities research analysts have rated the stock with a Buy rating, twenty have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $179.96.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $150.97 on Wednesday. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The stock’s fifty day simple moving average is $139.49 and its two-hundred day simple moving average is $131.13. Biogen has a 1-year low of $110.04 and a 1-year high of $194.13. The stock has a market cap of $22.14 billion, a PE ratio of 14.43, a price-to-earnings-growth ratio of 1.20 and a beta of 0.13.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the sale, the insider owned 5,772 shares of the company’s stock, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new stake in Biogen in the first quarter worth approximately $26,000. Greykasell Wealth Strategies Inc. purchased a new stake in Biogen in the first quarter worth approximately $27,000. Vision Financial Markets LLC purchased a new stake in Biogen in the first quarter worth approximately $27,000. Elevation Point Wealth Partners LLC bought a new stake in Biogen in the second quarter valued at approximately $25,000. Finally, Zions Bancorporation National Association UT bought a new stake in Biogen in the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.